Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Behavioral and Electrophysiological Arguments in Favor of a Relationship between Impulsivity, Risk-Taking, and Success on the Iowa Gambling Task.

Giustiniani J, Joucla C, Bennabi D, Nicolier M, Chabin T, Masse C, Trojak B, Vandel P, Haffen E, Gabriel D.

Brain Sci. 2019 Sep 24;9(10). pii: E248. doi: 10.3390/brainsci9100248.

2.

Efficacy of transcranial direct current stimulation in reducing impulsivity in borderline personality disorder (TIMBER): study protocol of a randomized controlled clinical trial.

Teti Mayer J, Nicolier M, Gabriel D, Masse C, Giustiniani J, Compagne C, Vandel P, Pazart L, Haffen E, Bennabi D.

Trials. 2019 Jun 10;20(1):347. doi: 10.1186/s13063-019-3427-z.

3.

Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.

Hocine HR, Brunel S, Chen Q, Giustiniani J, San Roman MJ, Ferrat YJ, Palacios I, de la Rosa O, Lombardo E, Bensussan A, Charron D, Jabrane-Ferrat N, Al-Daccak R.

Stem Cells Transl Med. 2019 Sep;8(9):911-924. doi: 10.1002/sctm.18-0256. Epub 2019 Mar 28.

4.

Predictors of remission to antidepressants in late-life depression: a systematic review.

Masse C, Bennabi D, Giustiniani J, Haffen E, Sechter D, Vandel P.

Geriatr Psychol Neuropsychiatr Vieil. 2018 Jun 1;16(2):189-196. doi: 10.1684/pnv.2018.0728. Review.

PMID:
29877187
5.

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.

Menguy T, Briaux A, Jeunesse E, Giustiniani J, Calcei A, Guyon T, Mizrahi J, Haegel H, Duong V, Soler V, Brousset P, Bensussan A, Raymond Letron I, Le Bouteiller P.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2687-2698. doi: 10.1167/iovs.18-24024.

PMID:
29860455
6.

CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases.

Henry A, Boulagnon-Rombi C, Menguy T, Giustiniani J, Garbar C, Mascaux C, Labrousse M, Milas C, Barbe C, Bensussan A, Durlach V, Arndt C.

Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):2679-2686. doi: 10.1167/iovs.18-24021.

PMID:
29860454
7.

Evidence for a neural signature of musical preference during silence.

Joucla C, Nicolier M, Giustiniani J, Brunotte G, Noiret N, Monnin J, Magnin E, Pazart L, Moulin T, Haffen E, Vandel P, Gabriel D.

Int J Psychophysiol. 2018 Mar;125:50-56. doi: 10.1016/j.ijpsycho.2018.02.007. Epub 2018 Feb 20.

PMID:
29474854
8.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

9.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Oct 20;7:46888. doi: 10.1038/srep46888.

10.

Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231.

Garbar C, Mascaux C, Giustiniani J, Merrouche Y, Bensussan A.

Sci Rep. 2017 Aug 3;7(1):7201. doi: 10.1038/s41598-017-07489-x.

11.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720. No abstract available.

12.

Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Jan 24;7:41125. doi: 10.1038/srep41125. Erratum in: Sci Rep. 2017 Mar 16;7:44720. Sci Rep. 2017 Oct 20;7:46888.

13.

A β-Turn Motif in the Steroid Hormone Receptor's Ligand-Binding Domains Interacts with the Peptidyl-prolyl Isomerase (PPIase) Catalytic Site of the Immunophilin FKBP52.

Byrne C, Henen MA, Belnou M, Cantrelle FX, Kamah A, Qi H, Giustiniani J, Chambraud B, Baulieu EE, Lippens G, Landrieu I, Jacquot Y.

Biochemistry. 2016 Sep 27;55(38):5366-76. doi: 10.1021/acs.biochem.6b00506. Epub 2016 Sep 19.

PMID:
27641460
14.

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type.

Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R.

Int J Mol Sci. 2016 Aug 30;17(9). pii: E1433. doi: 10.3390/ijms17091433. Review.

15.

Caspase-cleaved Tau-D(421) is colocalized with the immunophilin FKBP52 in the autophagy-endolysosomal system of Alzheimer's disease neurons.

Meduri G, Guillemeau K, Dounane O, Sazdovitch V, Duyckaerts C, Chambraud B, Baulieu EE, Giustiniani J.

Neurobiol Aging. 2016 Oct;46:124-37. doi: 10.1016/j.neurobiolaging.2016.06.017. Epub 2016 Jul 5.

PMID:
27479154
16.

Identification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes.

De Masson A, Giustiniani J, Marie-Cardine A, Bouaziz JD, Dulphy N, Gossot D, Validire P, Tazi A, Garbar C, Bagot M, Merrouche Y, Bensussan A.

Oncoimmunology. 2016 Jan 13;5(5):e1127493. doi: 10.1080/2162402X.2015.1127493. eCollection 2016 May.

17.

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.

Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J.

Oncotarget. 2016 Aug 16;7(33):53350-53361. doi: 10.18632/oncotarget.10804.

18.

Don't forget the lyrics! Spatiotemporal dynamics of neural mechanisms spontaneously evoked by gaps of silence in familiar and newly learned songs.

Gabriel D, Wong TC, Nicolier M, Giustiniani J, Mignot C, Noiret N, Monnin J, Magnin E, Pazart L, Moulin T, Haffen E, Vandel P.

Neurobiol Learn Mem. 2016 Jul;132:18-28. doi: 10.1016/j.nlm.2016.04.011. Epub 2016 Apr 27.

PMID:
27131744
19.

Isomerization and Oligomerization of Truncated and Mutated Tau Forms by FKBP52 are Independent Processes.

Kamah A, Cantrelle FX, Huvent I, Giustiniani J, Guillemeau K, Byrne C, Jacquot Y, Landrieu I, Baulieu EE, Smet C, Chambraud B, Lippens G.

J Mol Biol. 2016 Mar 27;428(6):1080-1090. doi: 10.1016/j.jmb.2016.02.015. Epub 2016 Feb 20.

PMID:
26903089
20.

Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome.

Plée J, Le Jan S, Giustiniani J, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, Aubin F, Antonicelli F, Bernard P.

Sci Rep. 2015 Dec 14;5:18001. doi: 10.1038/srep18001.

21.

Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway.

Garbar C, Mascaux C, Giustiniani J, Salesse S, Debelle L, Antonicelli F, Merrouche Y, Bensussan A.

Int J Clin Exp Pathol. 2015 May 1;8(5):4344-55. eCollection 2015.

22.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

23.

Neural Correlates of Successful and Unsuccessful Strategical Mechanisms Involved in Uncertain Decision-Making.

Giustiniani J, Gabriel D, Nicolier M, Monnin J, Haffen E.

PLoS One. 2015 Jun 18;10(6):e0130871. doi: 10.1371/journal.pone.0130871. eCollection 2015.

24.

The FK506-binding protein FKBP52 in vitro induces aggregation of truncated Tau forms with prion-like behavior.

Giustiniani J, Guillemeau K, Dounane O, Sardin E, Huvent I, Schmitt A, Hamdane M, Buée L, Landrieu I, Lippens G, Baulieu EE, Chambraud B.

FASEB J. 2015 Aug;29(8):3171-81. doi: 10.1096/fj.14-268243. Epub 2015 Apr 17.

25.

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

Farren TW, Giustiniani J, Fanous M, Liu F, Macey MG, Wright F, Prentice A, Nathwani A, Agrawal SG.

Blood Cancer J. 2015 Jan 23;5:e273. doi: 10.1038/bcj.2014.92.

26.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

27.

Immunophilin FKBP52 induces Tau-P301L filamentous assembly in vitro and modulates its activity in a model of tauopathy.

Giustiniani J, Chambraud B, Sardin E, Dounane O, Guillemeau K, Nakatani H, Paquet D, Kamah A, Landrieu I, Lippens G, Baulieu EE, Tawk M.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4584-9. doi: 10.1073/pnas.1402645111. Epub 2014 Mar 12.

28.

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.

29.

[A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor].

Le Bouteiller P, Tabiasco J, Giustiniani J, Bensussan A.

Med Sci (Paris). 2012 Jan;28(1):37-8. doi: 10.1051/medsci/2012281013. Epub 2012 Jan 27. French. No abstract available.

30.

Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17.

Giustiniani J, Sineus M, Sardin E, Dounane O, Panchal M, Sazdovitch V, Duyckaerts C, Chambraud B, Baulieu EE.

J Alzheimers Dis. 2012;29(2):471-83. doi: 10.3233/JAD-2011-111895.

PMID:
22233767
31.

Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.

Giustiniani J, Alaoui SS, Marie-Cardine A, Bernard J, Olive D, Bos C, Razafindratsita A, Petropoulou A, de Latour RP, Le Bouteiller P, Bagot M, Socié G, Bensussan A.

Curr Mol Med. 2012 Feb;12(2):188-98.

PMID:
22172098
32.

Differential and tumor-specific expression of CD160 in B-cell malignancies.

Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D, Newland AC, Calaminici M, Bensussan A, Jenner M, Gribben JG, Agrawal SG.

Blood. 2011 Aug 25;118(8):2174-83. doi: 10.1182/blood-2011-02-334326. Epub 2011 Jun 28.

33.

Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes.

Mansur IG, Schiavon V, Giustiniani J, Bagot M, Bensussan A, Marie-Cardine A.

Immunol Lett. 2011 Sep 30;139(1-2):52-7. doi: 10.1016/j.imlet.2011.04.015. Epub 2011 May 11.

PMID:
21600927
34.

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.

Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ, Giustiniani J, Bellard E, Brayer S, Aguerre-Girr M, Meggetto F, Giuriato S, Malecaze F, Galiacy S, Jaïs JP, Chose O, Kadouche J, Chouaib S, Teissié J, Abitbol M, Bensussan A, Le Bouteiller P.

J Exp Med. 2011 May 9;208(5):973-86. doi: 10.1084/jem.20100810. Epub 2011 Apr 11.

35.

CD160: a unique activating NK cell receptor.

Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J, Berrebi A, Aguerre-Girr M, Bensussan A, Jabrane-Ferrat N.

Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13. Review.

PMID:
21324341
36.

Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.

Ortonne N, Ram-Wolff C, Giustiniani J, Marie-Cardine A, Bagot M, Mecheri S, Bensussan A.

J Invest Dermatol. 2011 Apr;131(4):916-24. doi: 10.1038/jid.2010.412. Epub 2010 Dec 30.

37.

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.

Liu FT, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, Agrawal SG.

Blood. 2010 Apr 15;115(15):3079-88. doi: 10.1182/blood-2009-08-239483. Epub 2010 Feb 17.

38.

A role for FKBP52 in Tau protein function.

Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, Goedert M, Baulieu EE.

Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2658-63. doi: 10.1073/pnas.0914957107. Epub 2010 Jan 25.

39.

Kinesin-1 regulates microtubule dynamics via a c-Jun N-terminal kinase-dependent mechanism.

Daire V, Giustiniani J, Leroy-Gori I, Quesnoit M, Drevensek S, Dimitrov A, Perez F, Poüs C.

J Biol Chem. 2009 Nov 13;284(46):31992-2001. doi: 10.1074/jbc.M109.007906. Epub 2009 Sep 16.

40.

Basal endothelial nitric oxide synthase (eNOS) phosphorylation on Ser(1177) occurs in a stable microtubule- and tubulin acetylation-dependent manner.

Giustiniani J, Couloubaly S, Baillet A, Pourci ML, Cantaloube I, Fourniat C, Paul JL, Poüs C.

Exp Cell Res. 2009 Dec 10;315(20):3509-20. doi: 10.1016/j.yexcr.2009.07.018. Epub 2009 Jul 24.

PMID:
19632222
41.

Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53.

Giustiniani J, Daire V, Cantaloube I, Durand G, Poüs C, Perdiz D, Baillet A.

Cell Signal. 2009 Apr;21(4):529-39. doi: 10.1016/j.cellsig.2008.12.004. Epub 2008 Dec 24.

PMID:
19136058
43.

Validation of biometric study of fetal mandibles by 3D tomodensitometric images.

Perez-Guevara S, Bartoli C, Giustiniani J, Adalian P, Piercecchi-Marti MD, Panuel M, Foti B, Leonetti G.

Bull Group Int Rech Sci Stomatol Odontol. 2006 Mar;47(1):11-7.

PMID:
17672200
44.
45.

Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.

Abecassis S, Giustiniani J, Meyer N, Schiavon V, Ortonne N, Campillo JA, Bagot M, Bensussan A.

J Invest Dermatol. 2007 May;127(5):1161-6. Epub 2007 Jan 11.

46.

The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function.

Rey J, Giustiniani J, Mallet F, Schiavon V, Boumsell L, Bensussan A, Olive D, Costello RT.

Eur J Immunol. 2006 Sep;36(9):2359-66.

47.

Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells.

Fons P, Chabot S, Cartwright JE, Lenfant F, L'Faqihi F, Giustiniani J, Herault JP, Gueguen G, Bono F, Savi P, Aguerre-Girr M, Fournel S, Malecaze F, Bensussan A, Plouët J, Le Bouteiller P.

Blood. 2006 Oct 15;108(8):2608-15. Epub 2006 Jun 29.

PMID:
16809620
48.

Protocadherin 15 (PCDH15): a new secreted isoform and a potential marker for NK/T cell lymphomas.

Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, Beaud G, Besnard F, Loyaux D, Ferrara P, Leroy K, Shimizu N, Gaulard P, Bensussan A, Schmitt C.

Oncogene. 2006 May 4;25(19):2807-11.

PMID:
16369489
49.

Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.

Bouaziz JD, Ortonne N, Giustiniani J, Schiavon V, Huet D, Bagot M, Bensussan A.

J Invest Dermatol. 2005 Dec;125(6):1273-8.

50.

New forensic approach to age determination in children based on tooth eruption.

Foti B, Lalys L, Adalian P, Giustiniani J, Maczel M, Signoli M, Dutour O, Leonetti G.

Forensic Sci Int. 2003 Mar 12;132(1):49-56.

PMID:
12689751

Supplemental Content

Loading ...
Support Center